```html

Sexually Transmitted Infections (STIs): A Complete Patient‑Friendly Guide

Overview

Sexually transmitted infections (STIs), formerly called sexually transmitted diseases (STDs), are infections that are passed from one person to another primarily through sexual contact—including vaginal, anal, or oral intercourse. More than 1 in 2 million Americans acquire an STI each year and worldwide there are an estimated 374 million new cases of chlamydia, gonorrhea, syphilis and trichomoniasis annually (WHO, 2023).

STIs can affect anyone who is sexually active, regardless of age, gender, sexual orientation, or socioeconomic status. However, the following groups have higher reported rates:

• People under 25 years old (they represent ~50 % of all new infections).
• Men who have sex with men (MSM) – especially for HIV, syphilis, and gonorrhea.
• Individuals with multiple or concurrent sexual partners.
• People living in areas with limited access to screening and treatment.

Most STIs are caused by bacteria (e.g., chlamydia, gonorrhea, syphilis) or viruses (e.g., HPV, herpes simplex virus, HIV). Some are caused by parasites (trichomoniasis) or fungi (candidiasis). Early detection and treatment dramatically reduce the risk of complications and onward transmission.

Symptoms

Many STIs are asymptomatic—meaning they cause no noticeable signs, especially in the early stages. When symptoms do appear, they can vary by infection, site of exposure (genital, oral, anal), and individual immune response. Below is a comprehensive symptom checklist.

Common genital symptoms

• Painful or burning urination – seen with chlamydia, gonorrhea, trichomoniasis, urethritis.
• Abnormal discharge – watery or mucous (chlamydia), thick yellow/green (gonorrhea), frothy gray (trichomoniasis).
• Genital sores or ulcers – painless (syphilis chancre), painful (herpes, chancroid).
• Genital warts – cauliflower‑like growths caused by certain HPV strains.
• Itching, redness, or irritation – common with candidiasis, trichomoniasis, and some viral infections.

Rectal and anal symptoms

• Rectal pain, bleeding, or discharge (anal gonorrhea, chlamydia, herpes).
• Anal warts (HPV) or ulcerations (herpes, syphilis).

Oral symptoms

• Sores or blisters on lips, gums, or throat (herpes simplex virus, syphilis).
• Persistent sore throat or swollen lymph nodes (gonnorrheal pharyngitis).

Systemic symptoms

• Fever, malaise, or muscle aches – often with primary syphilis, acute HIV infection, or disseminated gonorrhea.
• Swollen lymph nodes in the groin, neck, or armpits (most viral STIs).
• Pelvic pain or lower abdominal pain (PID from chlamydia/gonorrhea).
• Joint pain or skin rashes – seen with secondary syphilis or disseminated gonorrhea.

Because symptoms overlap between infections and many infections can be silent, routine screening is essential if you have any risk factors.

Causes and Risk Factors

STIs are caused by specific pathogens transmitted through sexual fluids or skin‑to‑skin contact. Below is a concise list of the most common infections and their causative agents.

Infection	Pathogen	Transmission
Chlamydia	Chlamydia trachomatis (bacterium)	Vaginal, anal, oral sex; perinatal
Gonorrhea	Neisseria gonorrhoeae (bacterium)	Vaginal, anal, oral sex; perinatal
Syphilis	Treponema pallidum (bacterium)	Direct contact with chancre or rash
Human Papillomavirus (HPV)	HPV (virus)	Skin‑to‑skin contact; genital, anal, oral
Herpes Simplex Virus (HSV‑1/2)	HSV (virus)	Contact with lesions or secretions
HIV	Human Immunodeficiency Virus	Blood, semen, vaginal fluids, breast milk
Trichomoniasis	Trichomonas vaginalis (protozoan)	Sexual contact
Candidiasis (yeast infection)	Candida albicans (fungus)	Overgrowth; can be sexually transmitted

Key risk factors

• Unprotected sex (no condom or dental dam).
• Multiple or new partners within a short time frame.
• Previous STI – infection can alter mucosal immunity.
• Substance use (alcohol, methamphetamine, poppers) that impairs judgment.
• Sexual practices with higher mucosal trauma (anal intercourse, rough vaginal sex).
• Pregnancy or hormonal contraception can change vaginal flora.
• Low socioeconomic status or limited access to healthcare – reduces screening opportunities.

Diagnosis

Accurate diagnosis relies on a combination of a thorough sexual history, physical examination, and specific laboratory tests. Below are the most commonly used diagnostic tools.

Screening Tests

• Nucleic Acid Amplification Tests (NAATs) – highly sensitive for chlamydia, gonorrhea, and Mycoplasma genitalium. Usually performed on urine or swabs.
• Rapid Antigen Tests – used for Trichomonas (point‑of‑care kits) and some HIV rapid tests.
• Serologic (blood) Tests – detect antibodies for syphilis (RPR/VDRL followed by confirmatory treponemal test), HIV, and HSV.
• Pap smear with HPV testing – screens for high‑risk HPV types and cervical precancers.
• Culture and Sensitivity – reserved for gonorrhea when antibiotic resistance is suspected.

Physical Exam Findings

During a genital, anal, or oral exam, clinicians look for:

• Ulcers, vesicles, or warts.
• Discharge or erythema.
• Enlarged lymph nodes.
• Signs of pelvic inflammatory disease (PID) – cervical motion tenderness.

When to Test

• Any unprotected sexual encounter.
• New or multiple partners.
• Pregnancy (routine prenatal screening for chlamydia, gonorrhea, syphilis, HIV, HBV).
• Symptoms suggestive of an STI.
• Partner notification or known exposure.

Treatment Options

Most bacterial STIs are curable with antibiotics, whereas viral infections are managed with antiviral medications or supportive care.

Antibiotic Regimens (Bacterial STIs)

• Chlamydia: Azithromycin 1 g orally single dose *or* Doxycycline 100 mg orally twice daily for 7 days (CDC 2024).
• Gonorrhea: Ceftriaxone 500 mg IM single dose *plus* Azithromycin 1 g orally (dual therapy to deter resistance).
• Syphilis: Benzathine penicillin G 2.4 million units IM single dose for primary/secondary disease; weekly for 3 weeks for late latent.
• Trichomoniasis: Metronidazole 2 g orally single dose or 500 mg twice daily for 7 days.

Antiviral Therapy (Viral STIs)

• Herpes Simplex Virus: Acyclovir 400 mg PO three times daily, Valacyclovir 500 mg PO twice daily, or Famciclovir 250 mg PO three times daily for 7‑10 days (first‑episode). Suppressive therapy (daily) reduces recurrences.
• Human Papillomavirus: No antiviral; treatment focuses on lesion removal (cryotherapy, topical imiquimod, surgical excision). Vaccination prevents infection with high‑risk types.
• HIV: Combination antiretroviral therapy (cART) – lifelong regimen tailored to resistance profile.

Procedural Interventions

• Drainage of abscesses or large genital warts.
• Laser or excisional surgery for high‑grade cervical intraepithelial neoplasia (CIN) caused by HPV.
• Therapeutic phimosis circumcision for recurrent ulcerative infections in uncircumcised men.

Lifestyle & Supportive Measures

• Abstain from sexual activity until treatment completion and symptom resolution.
• Notify all recent sexual partners so they can be tested and treated.
• Adhere to medication schedules; use reminders or pillboxes.
• Consider counseling for mental health impacts and safe‑sex education.

Living with Sexually Transmitted Infections (generic)

Being diagnosed with an STI can be stressful, but with proper management you can lead a healthy, active life.

Daily Management Tips

• Medication adherence – never skip doses; set alarms.
• Follow‑up testing – most infections require a test of cure (e.g., retest for chlamydia/gonorrhea 3 weeks after treatment).
• Safe sex practices – use condoms consistently, consider dental dams for oral sex.
• Regular screening – at least annually for sexually active individuals; more often if high risk.
• Vaccinations – HPV vaccine up to age 45, Hepatitis B vaccine, and annual flu shot.
• Pelvic health – stay hydrated, urinate after intercourse to reduce urinary‑tract irritation.
• Emotional health – seek support groups or counseling; many clinics provide confidential counseling.

Partner Communication

Open, honest conversations reduce repeat infections. Use “I” statements, share test results, and discuss condom use. If you feel unsafe, contact a trusted health professional or local sexual health hotline for advice.

Prevention

Prevention strategies address both behavioral and biomedical factors.

Behavioral Measures

• Consistent and correct use of latex or polyurethane condoms.
• Limit number of concurrent sexual partners.
• Avoid sexual activity while under the influence of substances that impair decision‑making.
• Engage in regular STI screening—especially after any new partnership.
• Practice good genital hygiene (gentle washing, avoid douching).

Biomedical Interventions

• HPV vaccination – 9‑valent vaccine protects against >90 % of cervical cancers.
• Pre‑exposure prophylaxis (PrEP) – daily Truvada/Descovy reduces HIV acquisition by >90 % for high‑risk individuals.
• Post‑exposure prophylaxis (PEP) – antiretroviral therapy started within 72 hours after potential HIV exposure.
• Male circumcision reduces acquisition of HIV, HSV‑2, and HPV in heterosexual men (WHO, 2022).

Complications

If left untreated, STIs can lead to short‑ and long‑term health problems.

• Pelvic Inflammatory Disease (PID) – scarring of fallopian tubes, chronic pelvic pain, infertility (chlamydia, gonorrhea).
• Infertility – in both men (epididymitis, prostatitis) and women (PID, tubal blockage).
• Increased HIV susceptibility – genital ulcers provide entry points.
• Neonatal infections – conjunctivitis, pneumonia, or sepsis from maternal chlamydia, gonorrhea, syphilis, or HIV.
• Cancers – persistent high‑risk HPV infection leads to cervical, anal, or oropharyngeal cancers.
• Chronic pain syndromes – e.g., prostatitis, epididymitis.
• Systemic disease – secondary syphilis (rash, fever), disseminated gonorrhea (joint pain, skin lesions).

When to Seek Emergency Care

---

Sources: Centers for Disease Control and Prevention (CDC). 2024 STI Treatment Guidelines.
World Health Organization (WHO). 2023 Global STI Report.
Mayo Clinic. “Sexually transmitted infections (STIs) – Overview.”
National Institutes of Health (NIH). “HPV vaccine safety and efficacy.”
Cleveland Clinic. “Pelvic inflammatory disease (PID).”

```